LRRK2
Los inhibidores de LRRK2 son compuestos que se dirigen y inhiben la actividad de la quinasa rica en repeticiones de leucina 2 (LRRK2), una enzima involucrada en varios procesos celulares, como la autofagia, el tráfico vesicular y la inflamación. Las mutaciones en el gen LRRK2 están asociadas con un mayor riesgo de desarrollar la enfermedad de Parkinson, lo que convierte a LRRK2 en un objetivo significativo para la investigación de enfermedades neurodegenerativas. Los inhibidores de LRRK2 son cruciales para explorar su papel en la enfermedad de Parkinson y para desarrollar posibles estrategias terapéuticas. En CymitQuimica, ofrecemos una selección de inhibidores de LRRK2 para apoyar su investigación en neurodegeneración, señalización de quinasas y desarrollo terapéutico.
Se han encontrado 43 productos de "LRRK2"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CZC-25146 hydrochloride
CAS:CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.Fórmula:C22H26ClFN6O4SPureza:98.76%Forma y color:SolidPeso molecular:525JH-II-127
CAS:JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).Fórmula:C19H21ClN6O3Pureza:98.32%Forma y color:SolidPeso molecular:416.86Ref: TM-T7155
2mg43,00€5mg66,00€1mL*10mM (DMSO)73,00€10mg96,00€25mg166,00€50mg259,00€100mg366,00€200mg520,00€IKK 16
CAS:IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Fórmula:C28H29N5OSPureza:98.76% - 99.61%Forma y color:SolidPeso molecular:483.63Ref: TM-T6176
1mg38,00€2mg50,00€5mg84,00€1mL*10mM (DMSO)93,00€10mg132,00€25mg233,00€50mg385,00€100mg550,00€200mg782,00€CZC-25146
CAS:CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Fórmula:C22H25FN6O4SPureza:97.68%Forma y color:SolidPeso molecular:488.54GNE-9605
CAS:GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).Fórmula:C17H20ClF4N7OPureza:98.55% - 98.75%Forma y color:SolidPeso molecular:449.83GNE-7915
CAS:GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.Fórmula:C19H21F4N5O3Pureza:98% - ≥95%Forma y color:SolidPeso molecular:443.4Ref: TM-T1945
5mg44,00€1mL*10mM (DMSO)48,00€10mg58,00€25mg108,00€50mg177,00€100mg299,00€200mg389,00€500mg645,00€CZC-54252
CAS:CZC-54252 is a potent inhibitor of LRRK2.Fórmula:C22H25ClN6O4SPureza:99.39%Forma y color:SolidPeso molecular:504.99LRRK2-IN-10
CAS:LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Fórmula:C20H15N5OPureza:98%Forma y color:SolidPeso molecular:341.37PF-06455943
CAS:PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32PF-06371900
CAS:PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).Fórmula:C17H16N6O2SForma y color:SolidPeso molecular:368.41LRRK2-IN-7
CAS:LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Fórmula:C24H26N6OPureza:99.26%Forma y color:SolidPeso molecular:414.5LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Fórmula:C18H17ClN8O2Forma y color:SolidPeso molecular:412.83LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Fórmula:C24H32ClN7OForma y color:SolidPeso molecular:470.01LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Fórmula:C19H19ClN8O2Forma y color:SolidPeso molecular:426.86LRRK2-IN-14
CAS:LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Fórmula:C17H18F3N5O2Forma y color:SolidPeso molecular:381.35(R,R)-LRRK2-IN-7
CAS:(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Fórmula:C24H26N6OPeso molecular:414.50LRRK2-IN-3
CAS:LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Fórmula:C25H29ClF2N6O2Forma y color:SolidPeso molecular:518.99LRRK2-IN-2
CAS:LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Fórmula:C23H23Cl2F3N6O2Forma y color:SolidPeso molecular:543.37LRRK2-IN-16
CAS:LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.Fórmula:C18H19N5OSForma y color:SolidPeso molecular:353.441LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Fórmula:C24H26F2N4O2SForma y color:SolidPeso molecular:472.55
